Publications by authors named "Jiyeong An"
Conversion therapy is a treatment strategy that shifts from palliative systemic therapy to curative surgical treatment for primary and/or metastatic stage IV gastric cancer (GC). To address its clinical statements, the Korean Gastric Cancer Association aims to present a consensus on conversion therapy among experts attending KINGCA WEEK 2024. The KINGCA Scientific Committee and Development Working Group for Korean Practice Guidelines prepared preformulated topics and 9 clinical statements for conversion therapy.
View Article and Find Full Text PDFArticle Synopsis
- Advances in chemotherapy and immunotherapy have allowed some stage IV gastric cancer patients to undergo conversion surgery after significant tumor regression from palliative chemotherapy.
- A study involving 118 patients at Samsung Medical Center evaluated various baseline and post-chemotherapy features, finding that 21 patients achieved a complete pathologic response and 97 patients were downstaged.
- Important factors for prognostic evaluation included BMI, HER2 status, and other molecular markers, suggesting that conversion surgery can be an option for more patients regardless of their initial disease severity.
Background: REGATTA trial failed to demonstrate the survival benefit of reduction gastrectomy in patients with advanced gastric cancer with a single non-curable factor. However, a significant interaction was found between the treatment effect and tumor location in the subset analysis. Additionally, the treatment effect appeared to be different between Japan and Korea.
View Article and Find Full Text PDFBackground: Caucasian patients with microsatellite instability (MSI)-high gastric cancer (GC) may have better prognosis but worse outcomes.
Objective: Here we explored the prognostic role of MSI in Asian patients.
Methods: This post hoc analysis comprehended radically resected GC patients randomized to XP (capecitabine/cisplatin) or XPRT.
Scope: Peroxisome proliferator-activated receptor alpha (PPAR-α) is a ligand-activated transcription factor that regulates lipid and carbohydrate metabolism. We investigate the effects of naturally occurring PPAR-α agonists, phytol, and its metabolite phytanic acid, on obesity-induced metabolic disorders using a mouse model.
Methods And Results: A luciferase reporter assay shows that phytanic acid potently activates PPAR-α among PPAR subtypes.